These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1531828)

  • 41. Toxic hepatitis associated with paroxetine.
    Colakoglu O; Tankurt E; Unsal B; Ugur F; Kupelioglu A; Buyrac Z; Akpinar Z
    Int J Clin Pract; 2005 Jul; 59(7):861-2. PubMed ID: 15963219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Driving fitness in therapy with antidepressive drugs].
    Soyka M; Dittert S; Gartenmeier A; Schäfer M
    Versicherungsmedizin; 1998 Apr; 50(2):59-66. PubMed ID: 9587241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of the psychomotor effects of paroxetine.
    Hindmarch I
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():65-7. PubMed ID: 1431014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The safety of antidepressants.
    de Jonghe F; Swinkels JA
    Drugs; 1992; 43 Suppl 2():40-6; discussion 46-7. PubMed ID: 1378373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An interim overview of the safety and tolerability of paroxetine.
    Dunbar GC
    Acta Psychiatr Scand Suppl; 1989; 350():135-7. PubMed ID: 2530767
    [No Abstract]   [Full Text] [Related]  

  • 46. The pharmacokinetics of paroxetine in elderly depressed patients.
    Ghose K
    Acta Psychiatr Scand Suppl; 1989; 350():87-8. PubMed ID: 2530797
    [No Abstract]   [Full Text] [Related]  

  • 47. EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers.
    McClelland GR; Raptopoulos P
    Psychopharmacology (Berl); 1984; 83(4):327-9. PubMed ID: 6238338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs.
    Delini-Stula A; Fischbach R; Gauthier JM; Richou H; Rothweiler G; Wendt G; Wolfersdorf M
    Int Clin Psychopharmacol; 1987 Jul; 2(3):201-15. PubMed ID: 3320185
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antidepressant evaluation and the pharmacological actions of FG4963 in depressive patients.
    Ghose K; Gupta R; Coppen A; Lund J
    Eur J Pharmacol; 1977 Mar; 42(1):31-7. PubMed ID: 321228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The pharmacokinetics of paroxetine in renal impairment.
    Doyle GD; Laher M; Kelly JG; Byrne MM; Clarkson A; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():89-90. PubMed ID: 2530798
    [No Abstract]   [Full Text] [Related]  

  • 51. Paroxetine overdose.
    Gupta AK; Verma P; Praharaj SK; Roy D; Singh A
    Indian J Psychiatry; 2005 Jul; 47(3):167-8. PubMed ID: 20814462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of "paradoxical" antidepressant responses in young persons.
    Karanges EA; Kashem MA; Sarker R; Ahmed EU; Ahmed S; Van Nieuwenhuijzen PS; Kemp AH; McGregor IS
    Front Pharmacol; 2013; 4():86. PubMed ID: 23847536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spontaneous ejaculation with the use of noradrenergic reuptake inhibitors.
    Oosterhuis I; Heijting L; van Puijenbroek E
    Eur J Clin Pharmacol; 2012 Oct; 68(10):1461-2. PubMed ID: 22441314
    [No Abstract]   [Full Text] [Related]  

  • 54. [Drug flush. Possible role of indalpine overdosage].
    Manigand G; Dumont D; Taillandier J
    Presse Med; 1985 Apr; 14(15):841. PubMed ID: 3158908
    [No Abstract]   [Full Text] [Related]  

  • 55. Potential medication interactions with paroxetine use for cough in cancer patients.
    Wong AB; Hui L; Hong J
    J Oncol Pharm Pract; 2020 Jul; 26(5):1296. PubMed ID: 32279597
    [No Abstract]   [Full Text] [Related]  

  • 56. Paroxetine: safety and tolerability issues.
    Marks DM; Park MH; Ham BJ; Han C; Patkar AA; Masand PS; Pae CU
    Expert Opin Drug Saf; 2008 Nov; 7(6):783-94. PubMed ID: 18983224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.
    Telles-Correia D; Barbosa A; Cortez-Pinto H; Campos C; Rocha NB; Machado S
    World J Gastrointest Pharmacol Ther; 2017 Feb; 8(1):26-38. PubMed ID: 28217372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.
    Qirjazi E; McArthur E; Nash DM; Dixon SN; Weir MA; Vasudev A; Jandoc R; Gula LJ; Oliver MJ; Wald R; Garg AX
    PLoS One; 2016; 11(8):e0160768. PubMed ID: 27513855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia.
    Leonard CE; Bilker WB; Newcomb C; Kimmel SE; Hennessy S
    Pharmacoepidemiol Drug Saf; 2011 Sep; 20(9):903-13. PubMed ID: 21796718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.